Studier kring inflammatorisk tarmsjukdom

Artiklar

Eisenstein M. 
Biology: A slow-motion epidemic. 
Nature. 2016 Dec 21;540(7634):S98-S99. 

D'Haens GR et al.
Future directions in inflammatory bowel disease management 
J Crohns Colitis. 2014 Aug;8(8):726-34. 

Gomollón F et al
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
J Crohns Colitis. 2017 Jan;11(1):3-25. 

Gionchetti P et al
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations 
J Crohns Colitis. 2017 Feb;11(2):135-149. 

Magro F et al
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders
J Crohns Colitis. 2017 Jun 1;11(6):649-670. 

Harbord M et al
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
J Crohns Colitis. 2017 Jul 1;11(7):769-784. 
 

Farkas K and Molnár T
A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease
Immunotherapy. 2018 Feb;10(2):107-117. 

Studier

Sandborn WJ et al
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
Gastroenterology. 2008 Oct;135(4):1130-41. 

Reinisch W et al
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies 
Inflamm Bowel Dis. 2012 Feb;18(2):201-11. 

Yajnik V et al
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age Adv Ther. 2017 Feb;34(2):542-559. 

Schmitz EMH et al. 
Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study
Aliment Pharmacol Ther. 2018 Feb;47(3):356-363. 

Sandborn WJ et al
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
N Engl J Med. 2017 May 4;376(18):1723-1736.